Lilly Reports Higher Sales Led by Diabetes and Weight-Loss Medicines
Updated 23 September 2026
What Is Happening
Eli Lilly reported $23 billion in revenue for the second quarter of 2026, up 48% from a year earlier. The drugmaker attributed much of the growth to Mounjaro and Zepbound, two Lilly brands containing the same drug, tirzepatide. In the United States, Mounjaro is used for type 2 diabetes and Zepbound for weight management.
Lilly said sales volumes across the business rose 60%, while the prices the company received fell 13%. Selling more medicine outweighed the effect of those lower prices. The $23 billion is total company revenue, including other Lilly medicines; it is neither profit nor sales of the two leading products alone.
Lilly also raised the amount it expects to earn from sales during 2026 to $85 billion–$87 billion, from $82 billion–$85 billion. That forecast reflects the company’s expectations for the rest of the year and is separate from the quarterly sales already reported.
Sources (1)
Companies Involved
Eli Lilly
Eli Lilly develops and manufactures medicines for diabetes, obesity, cancer and other diseases.
Mentioned In
GLP-1 Market Monitor
Active companies
